𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Defining stage III disease in colorectal cancer—aspects on treatment and evaluation of survival

✍ Scribed by Kristoffer Derwinger; Göran Carlsson; Tor Ekman

Publisher
John Wiley and Sons
Year
2010
Tongue
English
Weight
136 KB
Volume
102
Category
Article
ISSN
0022-4790

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Survival after adjuvant 5-FU treatment f
Survival after adjuvant 5-FU treatment for stage III colon cancer in hereditary nonpolyposis colorectal cancer
✍ Wouter H. de Vos tot Nederveen Cappel; Hielke J. Meulenbeld; Jan H. Kleibeuker; 📂 Article 📅 2004 🏛 John Wiley and Sons 🌐 French ⚖ 67 KB 👁 2 views

## Abstract __In vitro__ studies suggest that a deficient mismatch repair (MMR) system reduces 5‐Fluorouracil cytotoxicity. Colon cancer (CC) in hereditary nonpolyposis colorectal cancer (HNPCC) is due to a dysfunctioning MMR gene that leads to microsatellite instability (MSI). Clinical studies on

Delay in diagnosis of cancer. Possible e
Delay in diagnosis of cancer. Possible effects on the stage of disease and survival
✍ Professor; Head Eliezer Robinson; Judith Mohilever; Jemal Zidan; Dov Sapir 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 456 KB 👁 2 views

A total of 2299 new cancer patients were referred to the Northern Israel Oncology Center in 1974 and in 1980. The stage of disease, delay in diagnosis, the responsibility for the delay, and the survival of those referred in 1974 were investigated. At the time of diagnosis, 39% of the patients had lo

Pancreatic cancer treatment in the U.S.
Pancreatic cancer treatment in the U.S. veteran from 1987 to 1991: Effect of tumor stage on survival
✍ Terence P. Wade; William G. Kraybill; Katherine S. Virgo; Frank E. Johnson 📂 Article 📅 1995 🏛 John Wiley and Sons 🌐 English ⚖ 732 KB

To assess the outcomes after pancreatic cancer treatment in a nationwide hospital system, patients treated in Department of Veterans Affairs (DVA) hospitals from 1987 to 1991 were studied by tumor stage, the most significant reported influence on survival. Tumor registrars from DVA hospitals provide